TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01618214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
Study: NCT01595776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endothelial progenitor cells intramuscular implant
Description: After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
Study: NCT04455373

Intervention type: PROCEDURE
Intervention: pediatric vascular bypass grafting
Description: pediatric vascular bypass grafting

Intervention type: PROCEDURE
Intervention: pediatric vascular bypass grafting
Description: pediatric vascular bypass grafting
Study: NCT02875639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huoxue prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buyang huanwu decoction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QISHEN YIQI DRIPPING PILLS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo 1
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
Study: NCT01536860

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: 300 ml of liquid food product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 300 ml of liquid food product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 300 ml of liquid food product
Study: NCT03108950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement to Music
Description: The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
Study: NCT00684788

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: employment-based reinforcement
Description: Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages.
Study: NCT03579355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DFND Program
Description: The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
Study: NCT03592095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo needle
Description: Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
Study: NCT03757910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240
Description: This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-MK-6240
Description: This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
Study: NCT03466411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 4
Description: Guselkumab will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 5
Description: Guselkumab will be by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered by IV infusion and SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab will be administered by IV infusion and SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered by IV infusion and SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab will be administered by IV infusion and SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered by IV infusion and SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as IV infusion.
Study: NCT03757910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PIB
Description: This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-PIB
Description: This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
Study: NCT00571350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tvt-o operation
Description: transvaginal tention free obturator tape

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tvt o operation
Description: transobturator vaginal tape insertion
Study: NCT00944164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy eating and physical activity
Description: Parent counseling and coaching regarding healthy eating and physical activity habits for their child

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety and injury prevention
Description: Parent counseling and coaching regarding general personal and household safety
Study: NCT02640417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotides + B12
Description: Oral treatment with either Nucleotides + Vitamin B12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B Vitamins
Description: Oral treatment with vitamins B1, B6, and B12
Study: NCT03743870

Intervention type: DRUG
Intervention: Levobupivacaine
Description: Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.

Intervention type: DRUG
Intervention: Bupivacaine
Description: Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
Study: NCT01606111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl, saline
Description: IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
Study: NCT02475148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/high Calorie Breakfast
Study: NCT03038425

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
Study: NCT03158870

Intervention type: PROCEDURE
Intervention: Surgery complications
Description: Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
Study: NCT01993693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Diathermy Device
Description: The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Ultrasonic Diathermy Device
Description: Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
Study: NCT04640883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)
Description: Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (\>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of \~50% in load compared to habitual training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity cycling during a 14-day training camp (high training load)
Description: Five low-intensity cycling sessions (\>four hours per session), distance-matched to sprint group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recovery for 10 days (low training load)
Description: Habitual low-intensity cycling (\>0.5-2 hours per session)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery for 10 days (low training load)
Description: Habitual low-intensity cycling (\>0.5-2 hours per session)
Study: NCT03691792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT-SAD)
Description: 12 group sessions over 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Therapy
Description: 10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
Study: NCT03764852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outpatient laparoscopic
Description: The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outpatient laparoscopic
Description: The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
Study: NCT00540189

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initial appendectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interval appendectomy
Study: NCT01926483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
Study: NCT03442543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: preoperative localization of SLN detected by CTLG by either methods
Description: 50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel \& traditional method was performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: preoperative localization of SLN detected by CTLG by either methods
Description: 50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel \& traditional method was performed.
Study: NCT03884582

Intervention type: DEVICE
Intervention: Cova Monitoring System 3
Description: Healthy Volunteers
Study: NCT01727609

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk feed (breast milk or formula milk)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk feed (breast milk or formula milk)
Study: NCT02326415

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Pathway with Fast-Track
Description: Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Usual Protocol
Description: Cares step by step as sugery responsable thinks are the best for patients until discharge.
Study: NCT03840655

Intervention type: PROCEDURE
Intervention: Near-Infrared Imaging Thoracoscopy
Description: Sympathicotomy performed by near-infrared imaging thoracoscopy
Study: NCT04304027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored exercise intervention
Description: 2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at target heart rate reserve followed by 2 minutes working rest (target heart rate reserve may vary between sessions depending on the level of self-reported fatigue)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise intervention
Description: 2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at \>70% heart rate reserve followed by 2 minutes working rest
Study: NCT05113836

Intervention type: BIOLOGICAL
Intervention: Deep nasopharyngeal swab
Description: On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).

Intervention type: BIOLOGICAL
Intervention: Blood sample at D1, D3 and D7
Description: Specific samples for research and lipid analysis will be performed at D1, D3 and D7:~Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.~This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total).
Study: NCT02167932

Intervention type: BEHAVIORAL
Intervention: Walk With Ease
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
Study: NCT03524261

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study: NCT02833103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danshu Capsules
Description: Danshu Capsules (0.9g potid/day) for three months by oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinaverium Bromide
Description: Pinaverium Bromide (100mg potid/day) for three months by oral
Study: NCT01206205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months
Study: NCT05779072

Intervention type: DEVICE
Group type: OTHER
Intervention: Single Vision Soft Contact Lens
Description: Subjects refit to Single Vision Soft Contact Lens for 1 year

Intervention type: DEVICE
Group type: OTHER
Intervention: Single Vision Soft Contact Lens
Description: Subjects refit to Single Vision Soft Contact Lens for 1 year
Study: NCT00506883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Colchicine (4.8 mg total dose)
Description: At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Colchicine (1.8mg total dose)
Description: At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
Study: NCT02870309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
Study: NCT03759626

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impulsive intervention
Description: As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reflective Intervention
Description: This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study.